NDAINJECTIONINJECTABLE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 320 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1988.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 320 (ioversol) is an injectable radiographic contrast agent used to enhance visualization during X-ray imaging procedures. It works through X-ray contrast activity to improve diagnostic image quality in patients undergoing diagnostic imaging studies. This non-ionic, low-osmolarity contrast medium is administered intravenously for cardiovascular, cerebral, and general radiographic procedures.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on market defense and cost management rather than growth initiatives.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPTIRAY 320 offers limited growth opportunities given its LOE-approaching status and zero linked job openings; however, it provides solid experience in mature product management, payer negotiations, and generic defense strategies. Career trajectory on this product is best suited for professionals interested in contract management and market access optimization rather than innovation or launch execution.
Brand Manager
Worked on OPTIRAY 320 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.